Tradition, teamwork, and tailored treatment: Surgical oncology in the genomic era

Archives of Otolaryngology - Head and Neck Surgery

Volumn 135, Issue 4, 2009, Pages 337-341

  Wolf, Gregory T ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CISPLATIN; ERLOTINIB; PROTEIN TYROSINE KINASE INHIBITOR;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL TRIAL; CONFERENCE PAPER; GENOMICS; HEAD AND NECK CANCER; HUMAN; LARYNX CANCER; MOLECULAR GENETICS; MORBIDITY; ONCOLOGY; RECEPTOR BLOCKING; SURGEON; TEAMWORK; ARTICLE; EAR NOSE THROAT SURGERY; GENETICS; HEAD AND NECK TUMOR; PATIENT CARE; RISK ASSESSMENT;

GENOMICS; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM STAGING; OTORHINOLARYNGOLOGIC SURGICAL PROCEDURES; PATIENT CARE TEAM; RISK ASSESSMENT;

EID: 66149134487     PISSN: 08864470     EISSN: 08864470     Source Type: Journal    
DOI: 10.1001/archoto.2009.12     Document Type: Conference Paper

References (29)

1. Tarpley J L, Chretien P B, Alexander J C Jr, Hoye R C, Block J B, Ketcham A S. High dose methotrexate as a preoperative adjuvant in the treatment of epider moid carcinoma of the head and neck: a feasibility study and clinical trial. Am J Surg. 1975;130(4):481-486.
2. Jacobs C, Goffinet D R, Goffinet L, Kohler M, Fee W E. Chemotherapy as a substitute for surgery in the treatment of advanced, resectable head and neck cancer: a report from the Northern California Oncology Group. Cancer. 1987;60 (6):1178-1183.
3. Hong W K, Popkin J D, Shapshay S M. Preoperative adjuvant induction chemotherapy in head and neck cancer. In: Wolf GT, ed. Head and Neck Oncology. Boston, MA: Martinus Nijhoff Publishers; 1984:287-300.
4. The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991;324(24):1685-1690.
5. Urba S G, Moon J, Giri P G S, et al. Organ preservation for advanced resectable cancer of the base of tongue and hypopharynx: a Southwest Oncology Group Trial. J Clin Oncol. 2005;23(1):88-95.
6. Hoffman H T, Porter K, Karnell L H, et al. Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. Laryngoscope. 2006; 116(9, pt 2)(suppl 111):1-13.
7. Chen A Y, Halpern M. Factors predictive of survival in advanced laryngeal cancer. Arch Otolaryngol Head Neck Surg. 2007;133(12):1270-1276.
8. Urba S, Wolf G, Eisbruch A, et al. Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm. J Clin Oncol. 2006;24(4):593-598.
9. Bradford C R, Wolf G T, Carey TE, et al. Predictive markers for response to chemotherapy, organ preservation, and survival in patients with advanced laryngeal carcinoma. Otolaryngol Head Neck Surg. 1999;121(5):534-538.
10. Kumar B, Cordell K G, D'Silva N, et al. Expression of p53 and Bcl-xLas predictive markers for larynx preservation in advanced laryngeal cancer. Arch Otolaryngol Head Neck Surg. 2008;134(4):363-369.
11. Truelson J M, Fisher S G, Beals T E, McClatchey K D, Wolf G T; Department of Veterans Affairs Cooperative Laryngeal Cancer Study Group. DNA content and histologic growth pattern correlate with prognosis in patients with advanced squamous cell carcinoma of the larynx. Cancer. 1992;70(1):56-62.
12. Wolf G T. Integrating surgery into treatment paradigms for organ preservation: tailoring treatment to biology improves outcomes. Int J Radiat Oncol Biol Phys. 2007;69(2)(suppl):S4-S7.
13. Bauer J A, Kumar B, Cordell KG, et al. Targeting apoptosis to overcome cisplatin resistance: a translational study in head and neck cancer. Int J Radiat Oncol Biol Phys. 2007;69(2)(suppl):S106-S108.
14. American Association for Cancer Research. Targeting p53-MDM2 interaction using a potent MDM2 inhibitor to overcome cisplatin resistance in head and necksquamous cell carcinoma. http://www.aacrmeetingabstracts.org/cgi/content /meeting-abstract/2007/1-Annual-Meeting/3202?maxtoshow=&HITS=10&hits= 10&RESULTFORMAT=1&author1=kumar&andorexacttitle=and& andorexacttitleabs=and&searchid=1&FIRSTINDEX=40&sortspec=relevance &fdate =1/1/2007&tdate=12/31/2008&resourcetype=HWCIT. Accessed August 4,2008.
15. Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002;62(24):7350-7356.
16. Grandis JR, Tweardy DJ. TGF-αand EGFR in head and neck cancer. J Cell Bio- chem Suppl. 1993;17F:188-191.
17. Bonner JA, Harari PM, Giralt J, etal. Radiotherapy plus cetuximab for squamous- cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567-578.
18. Gillison ML, D'Souza G, Westra W, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst. 2008;100(6):407-420.
19. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 2007;356(19):1944-1956.
20. Licitra L, Perrone F, Bossi P, et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol. 2006;24(36):5630-5636.
21. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human pap- illomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008;100(4):261-269.
22. Prince ME, Sivanandan R, Kaczorowski A, et al. Identification of a subpopula-tion of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A. 2007;104(3):973-978.
23. β. E-cadherin, cyclin A1 and cytoglobin in oral cancer: quantitative evaluation using pyrosequencing. Br J Cancer. 2006;94(4):561-568.
24. Shibata M, Kodani I, Osaki M, et al. Cyclo-oxygenase-1 and-2 expression in human oral mucosa, dysplasias and squamous cell carcinomas and their pathological significance. Oral Oncol. 2005;41(3):304-312.
25. Duffy SA, Khan MJ, Ronis DL, et al. Health behaviors of head and neck cancer patients the first year after diagnosis. Head Neck. 2008;30(1):93-102.
26. Duffy SA, Ronis DL, McLean S, et al. Pretreatment health behaviors predict success among patients with head and neck squamous carcinoma. J Clin Oncol.In press.
27. Duffy AS, Taylor J, Terrell J, et al. Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer. 2008;113(4):750-757.
28. Kumar B, Cordell KG, Lee JS, et al. EGFR, p16, HPV Titer, Bcl-xL and p53,sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol. 2008;26(19):3128-3137.
29. Restructuring the NCI Clinical Trials Enterprise. NCI Cancer Bull. 2005;2(23):3.